In a small study of men with low bone mineral density (BDM) living with HIV and taking anti-retroviral therapy, both zoledronate or denosumab were well tolerated and effective for bone mineral density of the lumbar spine and femoral neck.

In a small study of men with low bone mineral density (BDM) living with HIV and taking anti-retroviral therapy, both zoledronate or denosumab were well tolerated and effective for bone mineral density of the lumbar spine and femoral neck.
Treatment with denosumab for patients with RA and glucocorticoid-induced osteoporosis led to greater increases in bone mineral density of the lumbar spine and hips of patients than treatment with risedronate.
Ohio State University Rheumatology Fellowship Program: Nina Couette, DO; Jesse Reisner, DO; & Sheryl Mascarenhas, MD, Fellowship Program Director |
Editor’s note: RheumMadness is the place for everyone crazy about rheumatology to connect, collaborate, compete and learn together. During RheumMadness, rheumatology concepts represent teams that compete against each other in a tournament, much like basketball teams do in the NCAA’s March Madness tournament. In a series for The Rheumatologist, readers will get a chance to…
Wake Forest School of Medicine Rheumatology Fellowship Program: Khiem Vu, MD; Alyssa Strazanac, MD; John Herion, DO; & Rami Diab, MD |
Daily living, such as walking, jumping and going up stairs, can be difficult for patients with osteoarthritis (OA). Research on the regenerative limbs of the axolotl and the human ankle provides insights into the potential of this process in humans and its implications for hip, knee and ankle OA.
Lisa Rapaport |
(Reuters Health)—It takes 12.4 months of bisphosphonate therapy to prevent one nonvertebral fracture per 100 postmenopausal women with osteoporosis, a meta-analysis of randomized clinical trials suggests.1 Researchers examined data on 10 randomized clinical trials with a total of 23,384 women who had an osteoporosis diagnosis based on either existing vertebral fractures or a bone mineral…
In the ACR Convergence 2021 session on Updates in OA, presenters discuss the debate over OA phenotypes vs. endotypes, as well as note that research conducted over the past 20 years yields a better understanding of the pathogenesis of OA.
Marilynn Larkin |
NEW YORK (Reuters Health)—In patients with knee osteoarthritis (OA), telehealth-delivered exercise and diet programs are superior to electronic health information for reducing pain and improving function, although the contribution of diet is modest, a randomized trial shows.1 “This research provides evidence from a large clinical trial to help tease out how much benefit dietary weight…
ACR Convergence 2021—On Nov. 5, Karen H. Costenbader, MD, MPH, professor of medicine, Harvard Medical School, and director of the lupus program, Brigham and Women’s Hospital, Boston, gave a whirlwind review of the most important clinical rheumatology publications of the past year. Testing New Medications for Rheumatic Disease ADVOCATE Trial of Avacopan Dr. Costenbader first…
Kade L. Paterson, PhD, BPod, BAppSci(Hons), Marian T. Hannan, DSc, MPH, Lara Chapman, MSc, BPod, Edward Roddy, DM, FRCP, Hylton B. Menz, PhD, BPod, & Catherine Bowen, PhD, BPod |
The high prevalence and significant burden of osteoarthritis (OA) are well known. But it’s becoming apparent that OA research efforts don’t necessarily match disease prevalence or disability. The International Foot and Ankle Osteoarthritis Consortium (IFOAC) is an international organization of volunteers that seeks to highlight a major and often overlooked problem in OA research—foot and…
Convex-walking shoes, dietary supplements, advancements in nerve growth factor inhibitors and more—Xavier Chevalier gave an overview and new insights into treatments for osteoarthritis.